Fig. 6
The synergistic effects of BTZ and 3-MA in vivo. a Experimental schema for testing the efficacy of BTZ and 3-MA in vivo. Resistant REC-1 cells (5 × 106) were subcutaneously (s.c.) injected into NOD/SCID mice (n = 6). After the average tumor volume reached 50 mm3, xenografts #1–#3 were treated with BTZ alone (on Day 1 and 8) and xenografts #4–#6 were treated with BTZ (on Day 1 and 8) and 3-MA (on Day 2 and 9) for two weeks. Xenografts were then sacrificed on Day 15 for further analysis. D, day. b Representative s.c. tumors were photographed against a centimeter ruler (top), with their volumes under the photo. LC3II, p-AKT and AKT in tumor samples were measured using immunoblotting with Actin as a loading control (bottom). c Human CD45 (hCD45+) cells from spleen (SP) and bone marrow (BM) were analyzed using FCM. Data are presented as the mean ± SEM